Check for updates

OPEN ACCESS

EDITED BY Marcos Roberto De Oliveira, Federal University of Rio Grande do Sul, Brazil

REVIEWED BY John Sieh Dumbuya, Affiliated Hospital of Guangdong Medical University, China Sarah Farid, Ain Shams University, Egypt

*CORRESPONDENCE Aleksandra Ružičić, ⊠ a.ruzicic@bio.bg.ac.rs

RECEIVED 06 March 2025 ACCEPTED 14 April 2025 PUBLISHED 30 April 2025

CITATION

Ružičić A, Srdić T, Bobić K, Drakulić D, Veljković F, Todorović A, Đurašević S and Lakić I (2025) Region-specific neuroprotective effects of meldonium pretreatment in two models of sepsis-associated encephalopathy. *Front. Pharmacol.* 16:1588831. doi: 10.3389/fphar.2025.1588831

COPYRIGHT

© 2025 Ružičić, Srdić, Bobić, Drakulić, Veljković, Todorović, Đurašević and Lakić. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Region-specific neuroprotective effects of meldonium pretreatment in two models of sepsis-associated encephalopathy

Aleksandra Ružičić¹*, Tijana Srdić¹, Katarina Bobić², Dunja Drakulić², Filip Veljković³, Ana Todorović², Siniša Đurašević¹ and Iva Lakić¹

¹Department of Animal and Human Physiology, Institute for Physiology and Biochemistry Ivan Đaja, Faculty of Biology, University of Belgrade, Belgrade, Serbia, ²Department of Molecular Biology and Endocrinology, VINČA Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia, ³Department of Physical Chemistry, VINČA Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia

Sepsis-associated encephalopathy (SAE) is a common yet poorly understood complication of sepsis, which poses a burden in clinical settings, as its management relies on supportive care without targeted pharmacological interventions. Meldonium is a drug approved for ischemic heart disease but has also gained attention for its neuroprotective effects. In animal models of sepsis, meldonium pretreatment exerted antioxidative, antiapoptotic, and antiinflammatory effects, but its neurological effects have not been studied in SAE. In the present study, rats were pretreated with meldonium for 4 weeks, before sepsis was induced via a faecal intraperitoneal injection (FIP) or a lipopolysaccharide (LPS) injection. The cerebellum, medulla oblongata, and prefrontal cortex were examined due to their involvement in functions that are often impaired in sepsis. Eight hours post-sepsis induction, markers of brain injury were assessed, including reflexes scores, dry to wet brain mass ratio, prooxidant-antioxidant balance (PAB), advanced oxidation protein products (AOPP), lipid peroxidation (LPO), phosphatidylcholine (PC) to lysophosphatidylcholine (LPC) ratio, HMGB1 and haptoglobin protein expression, and CD73 activity. Meldonium-pretreated FIP-septic rats showed an earlier decline in reflex scores compared to the sepsis-only group, accompanied by a slight brain water accumulation. However, in both models of sepsis, meldonium pretreatment prevented alterations in the PAB, AOPP, and LPO in a region-specific manner. It also preserved the PC/LPC ratio in the prefrontal cortex of FIP-septic rats and in all regions of LPS-septic rats. Haptoglobin protein content was altered only in FIP-septic rats, and preserved by meldonium pretreatment in the cerebellum and medulla oblongata of these rats. Additionally, meldonium pretreatment preserved CD73 activity in the medulla oblongata and prefrontal cortex of FIP-septic rats and in the cerebellum and prefrontal cortex of LPS-septic rats. In conclusion, our study is the first to demonstrate that pretreatment with meldonium, a drug that has shown neuroprotective effects in other invasive models can also provide benefits in SAE, with the extent of protection depending on both the model of sepsis induction and the specific brain region investigated. Our findings support the

discussion on the importance of selecting the right sepsis model and studying individual brain regions when investigating SAE and potential therapeutic approaches.

KEYWORDS

sepsis, model, sepsis-associated encephalopathy (SAE), meldonium (mildronate), brain, rat

1 Introduction

Sepsis is a life-threatening condition caused by an uncontrolled immune response to an infection, and if not recognized and treated in time, it inevitably leads to organ failure and death (Singer et al., 2016). One of the most common complications is sepsis-associated encephalopathy (SAE), which encompasses both short- and longterm brain damage through mechanisms not fully elucidated (Catarina et al., 2021; Sekino et al., 2022). Proposed mechanisms of SAE onset and progression include disruption of cerebrovascular components and the blood-brain barrier (BBB), neurotransmitter and mitochondrial dysfunction, systemic inflammation, neuroinflammation (Aslankoc et al., 2018; Olivieri et al., 2018; Tian et al., 2019), oxidative stress (Aslankoc et al., 2018; Pan et al., 2022), hypoperfusion (Pfister et al., 2008), accumulation of damaged proteins (Brown, 2019; Kirk et al., 2019), direct brain damage (Sekino et al., 2022), etc. Current therapy for sepsis-induced brain injury focuses solely on treating the symptoms, as there are no treatment options that specifically target the underlying mechanisms of brain dysfunction (Sekino et al., 2022).

Meldonium (3-(2,2,2-trimethylhydrazinium) propionate) is the active substance of Mildronate® (Dambrova et al., 2002; Sesti et al., 2006), an orally administered prescription drug used in Eastern Europe for treating ischemic conditions of the heart and brain (Pupure et al., 2010a; Zhu et al., 2013; Kotov et al., 2015). When taken orally, meldonium is absorbed in the small intestine via active transport, enters the bloodstream where it binds to plasma lipids, and is transported into cells expressing the organic cation transporter 2 (OCTN2), which also facilitates its passage across the blood-brain barrier (Berlato and Bairros, 2020). Within the cell, meldonium inhibits the biosynthesis and transport of L-carnitine, thereby reducing the transport of free fatty acids (FAs) into the mitochondria and their subsequent oxidation (Dambrova et al., 2016). In this way, meldonium prevents the accumulation of harmful oxidative intermediates in the mitochondria (Dambrova et al., 2016). This is of particular interest in the context of sepsis, where mitochondrial damage due to excessive production of reactive oxygen species (ROS) leads to an increased energy demand (Zhang et al., 2018).

The neuroprotective properties of meldonium have been demonstrated in various experimental models (Sjakste et al., 2005; Pupure et al., 2010a; Pupure et al., 2010b; Zvejniece et al., 2010; Isajevs et al., 2011; Beitnere et al., 2014; Demir et al., 2019; Ozaydin et al., 2023). In the cortex of mice with azidothymidineinduced neurotoxicity, meldonium reduced infiltration of inflammatory cells and apoptosis (Pupure et al., 2010a). Similar observations were reported in the rat model of traumatic brain injury (Demir et al., 2019). In a model of peripheral nerve damage, meldonium halted neuronal degeneration, reduced neuroinflammation, and alleviated associated pain behavior (Pupure et al., 2010b). Ozaydin et al. recently reported meldonium's protective effects in rabbits with spinal cord injury (Ozaydin et al., 2023). In both seizure and ethanol intoxication rat models, a single intraperitoneal injection of meldonium exerted anticonvulsant and antihypnotic effects (Zvejniece et al., 2010). Perhaps most interestingly, in a mouse model of Alzheimer's disease, meldonium improved cognitive performance and reduced amyloid- β deposition in the hippocampus (Beitnere et al., 2014). In a rat model of Parkinson's disease, meldonium preserved the expression of proteins crucial for the neuronal protection (Isajevs et al., 2011).

Even though neuroprotective effects of meldonium have been demonstrated in other invasive models, present study, to our knowledge, would be the first to explore its potential benefits in the context of SAE. This requires the investigation of different brain regions, as regional susceptibility has been reported in sepsisinduced brain injury (Sharshar et al., 2003; Kafa et al., 2010; Heming et al., 2017). The cerebellum, medulla oblongata, and prefrontal cortex were chosen due to their critical roles in motor control, autonomic function, and higher cognitive processes, all of which are significantly affected in sepsis (Heming et al., 2017; Zhao et al., 2024). To fill these gaps, the present study investigated the effects of meldonium pretreatment on these brain regions in two commonly used models of experimentally induced sepsis.

2 Materials and methods

2.1 Ethical approval

All animals were obtained from the animal facility of the Faculty of Biology, University of Belgrade, Republic of Serbia. The animals were group-housed two per cage and acclimated to standard conditions at a temperature of $22^{\circ}C \pm 1^{\circ}C$ and a 12-h light-dark regime. Throughout the study, animals had *ad libitum* access to standard laboratory chow and water. Ethical approval for the experiments was granted by the Veterinary Directorate of the Serbian Ministry of Agriculture, Forestry and Water Management (permits No. 323-07-11574/2021-05 and 323-07-05650/2021-05/1). All procedures involving animals were performed in accordance with Serbian Animal Welfare Law, Directive 2010/63/EU, and the ARRIVE guidelines for reporting animal research. Given the invasiveness of the sepsis models, animal welfare was closely monitored and assessed based on behavior and general health status, with humane endpoints implemented accordingly.

2.2 Meldonium pretreatment

Analytical grade meldonium was purchased from Shenzhen Calson Bio-Tech Co. Ltd. (China). Meldonium was dissolved in

tap water, and fresh meldonium solution was prepared three times a week. The rats had ad libitum access to either tap water or meldonium solution via standard plastic bottles placed on the cages. Both body mass and daily consumption of water/ meldonium solution were monitored for 2 weeks before the experiment and throughout the 4-week meldonium treatment period. The concentration of the meldonium solution was adjusted to ensure a daily intake of 300 mg per kg of body mass. This dose, within the range of previously studied animal doses and corresponding to the manufacturer's recommended human dosage of Mildronate[®] when converted using the dose translation guide, also ensures comparability with our previous studies demonstrating the protective effects of meldonium (Liepinsh et al., 2009; Nair and Jacob, 2016; Đurašević et al., 2019; Berlato and Bairros, 2020). The 4week pretreatment duration was based on the meldonium-induced reduction of L-carnitine plateauing in rats at that point, with similar findings in human volunteers, and aligns with the manufacturer's recommendation for the treatment period with Mildronate® in ischemic conditions (Liepinsh et al., 2009; 2011; Berlato and Bairros, 2020).

2.3 FIP-induced sepsis

Nine-week-old male Sprague-Dawley rats weighing 329.91 ± 7.98 g were randomly divided into three experimental groups. The experimental groups were as follows: a sham control group (C) that received only tap water followed by a saline injection (n = 8), a sepsis group (S) that received tap water before sepsis induction (n = 14), and an M + S group (M + S) that received tap water with meldonium before sepsis induction (n = 16). To induce abdominal sepsis, rats were given a single faecal intraperitoneal (i.p.) injection (FIP) (Figure 1A). On the day before sepsis induction, the faeces of control animals were collected from the cage bedding, homogenized in saline solution, and mixed overnight at 4°C to reach a final concentration of 0.5 g/mL. The resulting suspension was filtered twice through quadruple gauze and administered at a dose of 5 g faeces per kg of body mass by a single i.p. with a 25G syringe. To control for bacterial load variability, all rats in the S and M + S groups received the same faecal solution, prepared in a single batch, and the solution was gently shaken before each injection to ensure its uniformity. The rats in the C group were injected i.p. with 10 mL of saline per kg of body mass.

2.4 LPS-induced sepsis

Nine-week-old male Sprague-Dawley rats, weighing 240.17 \pm 3.81 g, were randomly divided into three experimental groups (n = 8 each), following the same protocol as the FIP-induced sepsis model (Figure 1A). Rats had *ad libitum* access to tap water, with or without meldonium, for 4 weeks before sepsis was induced by a single i. p. injection of lipopolysaccharide (LPS) solution. On the day of sepsis induction, LPS was dissolved in saline to a final concentration of 5 mg/mL. The LPS solution was administered via a single i. p. injection using a 25G syringe at a dose of 5 mg per kg of body mass, a dose reported as effective for inducing SAE (Xin et al., 2022; Dumbuya et al., 2023). The rats in the C group received a single i. p. injection of 1 mL saline solution per kg of body mass.

2.5 Animal monitoring and scoring

After the injections, the rats were closely monitored every hour during the 8-h post-sepsis induction period. The presence of pinna reflex, corneal reflex, righting reflex, tail flexion and escape reflex was assessed as described in the literature (Haberham et al., 1999; Kafa et al., 2010). Each of the five reflexes examined was scored as follows: 0 for an absent reflex, 1 for a weak reflex, and 2 for a normal reflex.

2.6 Tissue collection and sample preparation

Since the mortality rate in FIP-septic rats pretreated with meldonium increases dramatically from the 8th hour after sepsis induction (Đurašević et al., 2021), to ensure a sufficient group size for subsequent analysis, rats were euthanized at this critical time point for tissue collection. The same endpoints were applied to LPS-induced sepsis to ensure comparability between the two models, although the LPS model is less invasive in terms of observed mortality (Đurašević et al., 2022).

Upon rapid decapitation using a stainless steel guillotine, the brain was quickly removed, and the cerebellum, medulla oblongata, and prefrontal cortex were immediately dissected on ice. Each brain region was then carefully divided into separate sections designated for different analyses described later, ensuring that freeze-thaw cycles were avoided. All samples were snap-frozen using liquid nitrogen and stored separately at -80°C. No samples were collected from rats that did not survive up to 8 h post-injection. A slightly modified previously described protocol was used to prepare the crude membrane fraction (P2) (Stanojlović et al., 2014). Briefly, individual brain structures were homogenized in ice-cold sucrose/Tris-HCl buffer (1:10 mass/volume ratio) using the IKA T 10 Basic Ultra Turrax Homogenizer (IKA®-Werke GmbH &Co. KG, Germany) and then centrifuged at $1,000 \times g$ for 10 min at 4°C (Microcentrifuge 5417R, Eppendorf, Germany) to remove unbroken tissue fragments, intact cells, large debris and nuclei and to obtain post-nuclear supernatant. The supernatants were transferred to new tubes and kept on ice, while the remaining pellets containing unhomogenized fragments and nuclei were detached from the tube walls by careful pipetting, resuspended in half of the initial volume of the homogenization buffer, and centrifuged under the same conditions. The resulting supernatants were gathered and centrifuged at $10,000 \times g$ for 20 min at 4°C. After discarding the resulting supernatants, the contain pellets that synaptosomes (nerve terminals). mitochondria, and a proportion of membrane fragments originating from lysed synaptosomes, neuronal, and glial cells, were gently resuspended in ice-cold 5 mM Tris-HCl buffer (pH 7.4). This fraction is referred to as an unpurified synaptosomal or crude membrane fraction (Gray and Whittaker, 1962). The protein concentration was determined according to the modified Lowry method (Markwell et al., 1978). All samples were aliquoted and stored at -80°C until further analysis.

Following dissection of brain regions of interest, the remaining brain tissue was swiftly weighed on an analytical balance to determine the wet mass. Each sample was placed on a piece of aluminum foil and dried in an oven at 180°C until it reached a



FIGURE 1

Effect of meldonium pretreatment on reflexes score and dry to wet brain mass ratio in septic rats. (A) The same study design was applied in both experimental models of sepsis. (B) In FIP-induced sepsis, M + S group showed an earlier and more sustained decline in reflexes score compared to the S group, with both groups demonstrating a slight increase in reflexes score towards the end of the observation period. (C) Dry to wet brain mass ratio suggested brain water accumulation in meldonium-pretreated FIP-septic rats, (D) while a similar trend was observed in LPS-induced sepsis, but it was not significant. All values are presented as mean \pm SEM. *, \star and # indicate P < 0.05 (*C vs. S; \star M + S vs. C; #M + S vs. S), as determined by one-way ANOVA with Tukey's or Kruskal–Wallis with Dunn's *post hoc* test, depending on data distribution. Abbreviations: FIP, intraperitoneal faecal injection; LPS, lipopolysaccharide; PC, phosphatidylcholine; LPC, lysophosphatidylcholine; CD73, cluster of differentiation 73; HMGB1, high mobility group box 1; HP, haptoglobin; C, sham control; S, sepsis; M + S, meldonium + sepsis.

constant mass, which represents the dry mass. The ratio of dry mass to wet brain mass was calculated and normalized to the C group.

2.7 Measurement of tissue oxidative stress indicators

Prooxidant-antioxidant balance (PAB) and advanced oxidation protein products (AOPP) were determined spectrophotometrically as previously described (Todorović et al., 2024).

To estimate concentration of end lipid peroxidation products (LPO) a modified method of Gérard-Monnier was used (Gérard-

Monnier et al., 1998). Briefly, methanesulfonic acid was added to the mixtures of sample/standard solution, 1-methyl-2phenylindole, and ferric chloride in acetonitrile/methanol (3:1 v/ v), and the mixtures were vortexed briefly. Following incubation for 1 h at 45°C in dark and centrifugation at 13,000 × g for 15 min at 4°C (Microcentrifuge 5417R, Eppendorf, Germany), the obtained supernatants were transferred to the wells of a microtiter plate, and the absorbance was measured at 586 nm using the SunriseTM Microplate Reader (Tecan Group Ltd, Switzerland). The standard curve was generated with dilutions of 1,1,3,3tetramethoxypropane, and sample concentrations were calculated in μ M.

2.8 Tissue analysis of phosphatidylcholine (PC) to lysophosphatidylcholine (LPC) intensity ratio

Upon total lipid extraction with Folch procedure (Folch et al., 1957), samples were resuspended in 0.5 M DHB (2,5dihydroxybenzoic acid) matrix solution, placed on the stainlesssteel target plate, and allowed to dry to obtain spectra by Voyager DE-Pro MALDI-TOF Mass Spectrometer (AB Sciex, United States) using nitrogen laser (337 nm), under reflector mode and "delayed extraction" conditions (with a delay time of approximately 100 ns) (Todorović et al., 2024). The spectra were processed using Data Explorer software version 4.9 (Applied Biosystems, United states). The most intense peaks of PC and LPC were used to calculate their intensity ratio for each experimental group.

2.9 Western blot analysis

Equal amounts of proteins (30 µg) were separated by 8%-15% SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore Sigma, United states). To confirm successful protein transfer, the membranes were stained with Ponceau S staining solution. To block non-specific binding of the primary antibody, PVDF membranes were incubated for 90 min at room temperature in 5% non-fat condensed milk (sc-2324, Santa Cruz Biotechnology, United states) dissolved in TBST buffer (0.2% Tween 20, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl). The membranes were then incubated overnight at 4°C with antibodies against high mobility group box 1 (HMGB1; 1:1,000, ab18256, Abcam, UK) and haptoglobin (1:500, ab256454, Abcam, UK). The membranes were then incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibody (1:30,000, ab6721, Abcam, UK). The immunoreactive bands were detected and recorded using the ChemiDoc-It gel/blot imager (UVP, Germany) after incubating the membranes with the chemiluminescent reagent (Clarity Western ECL, BioRad, United states) for 5 min. To re-probe membranes against the loading control, the secondary antibody was stripped following the Abcam mild stripping protocol and the membranes were then incubated for 1 h at room temperature with a horseradish peroxidase-conjugated anti-β-actin antibody (1:30,000, ab49900, Abcam, UK). Band quantification was performed using ImageJ software.

2.10 Measurement of ecto-5'-nucleotidase (CD73) activity

The ecto-5'-nucleotidase (CD73) activity was determined using the malachite green assay as previously reported (Drakulić et al., 2015).

2.11 Statistical analysis

Statistical analysis was performed using GraphPad Prism version 8.4.3 (GraphPad Software, Inc., United states). Outliers

were excluded from the datasets using the Robust Regression and Outlier Removal (ROUT) test with Q value set to 1%. Datasets that passed the Shapiro-Wilk normality test were subjected to one-way ANOVA analysis followed by post hoc analysis using Tukey's multiple comparisons test. The Kruskal-Wallis test was employed as a non-parametric alternative when the assumptions of normality were violated, and Dunn's multiple comparisons test was subsequently used for the post hoc analysis. To avoid redundancy, only P-values for post hoc analyses are reported in the manuscript, along with Z-values for Dunn's test and degrees of freedom (DF) for Tukey's test. The threshold for statistical significance was set at P < 0.05. At the endpoints, groups in LPS sepsis had a sample size of n = 8, whereas in FIP sepsis, due to mortality, the sample size was 8, 12, and 8 in the C, S, and M + S groups, respectively. All data are expressed as mean \pm standard error of the mean (SEM) and presented graphically relative to the control, unless otherwise stated.

3 Results

3.1 Effect of meldonium pretreatment on reflexes score and dry to wet brain mass ratio in septic rats

At the end of the 3rd hour post-FIP injection, only the M + S group showed a statistically significant decrease (Z = 2.721, P = 0.0195) in reflexes score compared to the C group (Figure 1B). In the 4th hour post-injection, this decrease became significant in both the S (Z = 2.971, P = 0.0089) and M + S groups (Z = 3.236, P = 0.0036) relative to the C group (Figure 1B). From the 6th hour towards the end of the observation period, both S and M + S groups showed a slight increase in reflexes score with the increase being relatively slower in the M + S group (Figure 1B). No decline in reflexes score was observed in rats with LPS-induced sepsis; hence no graph is included. The dry to wet brain mass ratio of meldonium-pretreated FIP-septic rats was significantly lower (Z = 2.835, P = 0.0137) compared to the sepsis-only group (Figure 1C). A similar but statistically insignificant trend was observed in the M + S group in the LPS model (Figure 1D).

3.2 Effect of meldonium pretreatment on oxidative stress biomarkers in the cerebellum, medulla oblongata, and prefrontal cortex of rats with FIPinduced sepsis

PAB levels were significantly elevated in all three brain regions of rats in the S group (cerebellum: Z = 2.92; P = 0.0103; medulla oblongata: Z = 2.85; P = 0.013; prefrontal cortex: DF = 20, P < 0.0001) in comparison to the C group (Figure 2A). However, in the cerebellum and medulla oblongata of M + S group they were similar to the control values, while in the prefrontal cortex, they were increased (DF = 20, P = 0.0259) compared to the C group (Figure 2A).

FIP sepsis led to a significant increase in AOPP levels in the medulla oblongata (DF = 24, P = 0.0171) and prefrontal cortex



FIGURE 2

Effect of meldonium pretreatment on oxidative stress biomarkers in cerebellum, medulla oblongata, and prefrontal cortex of rats with FIP-induced sepsis. Meldonium pretreatment prevented increases in (A) PAB, (B) AOPP, and (C) LPO levels observed in different brain regions following FIP-induced sepsis, in a region-specific manner. All values are presented as mean ± SEM. * and # indicate P < 0.05 (* vs. sham control; # vs. sepsis), as determined by one-way ANOVA with Tukey's or Kruskal–Wallis with Dunn's *post hoc* test, depending on data distribution. Abbreviations: FIP, intraperitoneal faecal injection; PAB, prooxidant-antioxidant balance; AOPP, advanced oxidation protein products; LPO, lipid peroxidation; m. oblongata, medulla oblongata; pf., prefrontal; C, sham control; S, sepsis; M + S, meldonium + sepsis.



FIGURE 3

Effect of meldonium pretreatment on oxidative stress biomarkers in cerebellum, medulla oblongata, and prefrontal cortex of rats with LPS-induced sepsis. In LPS-induced sepsis, meldonium maintained (A) PAB and (C) LPO at sham control levels in a region-specific manner, while (B) AOPP levels did not show significant changes across brain regions, with or without meldonium. All values are presented as mean \pm SEM. * and # indicate P < 0.05 (* vs. sham control; # vs. sepsis), as determined by one-way ANOVA with Tukey's or Kruskal–Wallis with Dunn's *post hoc* test, depending on data distribution. Abbreviations: LPS, lipopolysaccharide; PAB, prooxidant-antioxidant balance; AOPP, advanced oxidation protein products; LPO, lipid peroxidation; m. oblongata, medulla oblongata; pf., prefrontal; C, sham control; S, sepsis; M + S, meldonium + sepsis.

(DF = 19, P = 0.0357), whereas no such changes were observed in the rats pretreated with meldonium (Figure 2B). Additionally, similar levels of cerebellar AOPP were observed in all three experimental groups (Figure 2B).

LPO concentration in the cerebellum (DF = 25, P = 0.0009) and prefrontal cortex (DF = 19, P = 0.0055) in the S group increased significantly compared to the C group (Figure 2C). In meldoniumpretreated rats, cerebellar LPO levels were significantly decreased compared to those in FIP-septic rats (DF = 25, P = 0.0001), whereas in the prefrontal cortex no changes were observed (Figure 2C). In medulla oblongata, LPO remained at control values in both S and M + S groups (Figure 2C).

3.3 Effect of meldonium pretreatment on oxidative stress biomarkers in the cerebellum, medulla oblongata, and prefrontal cortex of rats with LPSinduced sepsis



LPS-septic rats. MALDI-TOF analysis revealed that meldonium maintained the PC/LPC ratio, an indicator of cell membrane integrity, in (A) the prefrontal cortex of FIP-septic rats and (B) in all three brain regions of LPS-septic rats. All values are presented as mean <u>+</u> SEM. * and # indicate P < 0.05 (* vs. sham control; # vs. sepsis), as determined by one-way ANOVA with Tukey's or Kruskal–Wallis with Dunn's *post hoc* test, depending on data distribution. Abbreviations: FIP, intraperitoneal faecal injection; LPS, lipopolysaccharide; PC, phosphatidylcholine; LPC, lysophosphatidylcholine; m. oblongata, medulla oblongata; pf., prefrontal; C, sham control; S, sepsis; M + S, meldonium + sepsis.

20, P = 0.0005) of the M + S group. In parallel, PAB levels in the medulla oblongata of the M + S group were similar to those in the S group and significantly increased compared to the C group (DF = 20, P = 0.0003; Figure 3A).

No significant changes in AOPP levels were observed in any of the brain regions examined after LPS injection, regardless of the pretreatment, when compared to the C group (Figure 3B). In the cerebellum of S group, LPO levels were increased significantly compared to the C group (DF = 20, P = 0.0008), while a similar trend was observed in medulla oblongata, but without statistical significance (Figure 3C). In these brain regions of M + S rats as well as in S rats, LPO levels were comparable to values observed in C group (Figure 3C) while in the prefrontal cortex of the M + S group, this parameter significantly increased (DF = 20, P = 0.0424; Figure 3C).

3.4 Effect of meldonium pretreatment on the PC/LPC intensity ratio in the cerebellum, medulla oblongata, and prefrontal cortex of septic rats

In obtained mass spectra in all experimental groups, the PC and LPC peaks were detected in two regions, 490–550 and 750–830 m/z. In sepsis groups of both experimental models, the PC/LPC intensity ratio in the prefrontal cortex was significantly decreased compared to the C group (both models: DF = 12; P < 0.0001; Figures 4A,B). However, in M +

S groups of both experimental models, PC/LPC ratio in the prefrontal cortex remained at control values and was significantly higher in comparison to the respective S group (both models: DF = 12; P < 0.0001; Figures 4A,B). When compared to C rats, in the cerebellum and medulla oblongata of FIP-septic rats, the PC/LPC ratio remained unchanged regardless of the pretreatment (Figure 4A). In LPS rats, however, the PC/LPC ratio was decreased in the cerebellum (DF = 11, P = 0.0001) but increased in the medulla oblongata (DF = 12, P = 0.0001) compared to C animals (Figure 4B). In these two structures in meldonium-pretreated LPS-septic rats, PC/LPC ratio was maintained at levels observed in C group (Figure 4B).

3.5 Effect of meldonium pretreatment on the HMGB1 and haptoglobin content in the cerebellum, medulla oblongata, and prefrontal cortex of rats with FIPinduced sepsis

No statistically significant changes in HMGB1 protein content were observed in any of the brain regions of FIP-septic rats in comparison to the C group (Figures 5A,B). In contrast, haptoglobin protein content was decreased in all three brain regions of rats in the S group compared to the C group (cerebellum: Z = 2.739, P = 0.0185; medulla oblongata: DF = 21; P = 0.0297; prefrontal cortex: DF = 17, P = 0.0029; Figures 5C,D). Such trend was observed in the M + S



FIGURE 5

Effect of meldonium pretreatment on HMGB1 and haptoglobin content in cerebellum, medulla oblongata, and prefrontal cortex of rats with FIPinduced sepsis. (A, B) Following FIP-induced sepsis, no changes in HMGB1 protein content were observed in either the S or M + S groups, as revealed by Western blot analysis. (C,D) Meldonium pretreatment significantly preserved haptoglobin content in the cerebellum and medulla oblongata, indicating a protective effect against FIP sepsis-induced haptoglobin depletion. All values are presented as mean \pm SEM. * and # indicate P < 0.05 (* vs. sham control; # vs. sepsis), as determined by one-way ANOVA with Tukey's or Kruskal–Wallis with Dunn's *post hoc* test, depending on data distribution. β -actin was used as a loading control. Abbreviations: FIP, intraperitoneal faecal injection; HMGB1, high mobility group box 1; m. oblongata, medulla oblongata; pf., prefrontal; C, sham control; S, sepsis; M + S, meldonium + sepsis.



FIGURE 6

Effect of meldonium pretreatment on HMGB1 and haptoglobin content in cerebellum, medulla oblongata, and prefrontal cortex of rats with LPSinduced sepsis. Following LPS-induced sepsis, no changes in (A,B) HMGB1 or (C,D) haptoglobin protein content were observed in any of the investigated brain regions, with or without meldonium, as revealed by Western blot analysis. All values are presented as mean \pm SEM. * and # indicate P < 0.05 (* vs. sham control; # vs. sepsis), as determined by one-way ANOVA with Tukey's or Kruskal–Wallis with Dunn's *post hoc* test, depending on data distribution. β -actin was used as a loading control. Abbreviations: LPS, lipopolysaccharide; HMGB1, high mobility group box 1; m. oblongata, medulla oblongata; pf., prefrontal; C, sham control; S, sepsis; M + S, meldonium + sepsis.



rats, sharpened that pretreatment with meldonium preserved CD73 activity (A) in the medulia oblongata and pretrontal cortex of EPS-septic rats, as well as (B) in the cerebellum and prefrontal cortex of EPS-septic rats, suggesting a protective effect that is dependent on both the brain region and the sepsis model investigated. All values are preserved as mean \pm SEM. * and # indicate P < 0.05 (* vs. sham control; # vs. sepsis), as determined by one-way ANOVA with Tukey's or Kruskal–Wallis with Dunn's *post hoc* test, depending on data distribution. Abbreviations: FIP, intraperitoneal faecal injection; LPS, lipopolysaccharide; CD73, cluster of differentiation 73; m. oblongata, medulla oblongata; pf., prefrontal; C, sham control; S, sepsis; M + S, meldonium + sepsis.

group in all three brain regions, but was statistically significant in the prefrontal cortex only (DF = 17, P = 0.0011; Figures 5C,D).

3.6 Effect of meldonium pretreatment on the HMGB1 and haptoglobin content in the cerebellum, medulla oblongata, and prefrontal cortex of rats with LPSinduced sepsis

No statistically significant changes in HMGB1 protein levels were observed in rats with LPS-induced sepsis, regardless of pretreatment (Figures 6A,B). Although not statistically significant, compared to C group, haptoglobin levels appeared to be downregulated in S group across all three brain structures; while they remained at control levels in M + S group (Figures 6C,D).

3.7 Effect of meldonium pretreatment on CD73 activity in the cerebellum, medulla oblongata, and prefrontal cortex of septic rats

The AMP hydrolysis rate, as an indicator of CD73 activity, was markedly reduced in the medulla oblongata (DF = 25, P = 0.0012) and prefrontal cortex (DF = 21, P = 0.0309) of the S group in comparison to the C group (Figure 7A). In these brain regions of FIP-septic rats pretreated with meldonium, CD73 activity was increased significantly compared to the S group (medulla

oblongata: DF = 25; P = 0.008; prefrontal cortex: DF = 21, P = 0.0001), whereas its cerebellar activity was similar between experimental groups (Figure 7A).

No statistically significant changes in CD73 activity were observed in the medulla oblongata of either meldoniumpretreated or non-pretreated LPS-septic rats in comparison to C group (Figure 7B). In two other regions, opposite patterns of CD73 activity were observed, with a higher AMP hydrolysis rate in the cerebellum (DF = 18, P = 0.0214) but a lower rate in the prefrontal cortex (DF = 19, P = 0.0365) of M + S rats compared to the S group (Figure 7B).

4 Discussion

Meldonium, marketed under the brand name Mildronate[®] and prescribed for ischemic conditions of the heart and brain, exerts its effects by inhibiting gamma-butyrobetaine hydroxylase, leading to reduced tissue levels of L-carnitine (Dambrova et al., 2016). This causes a shift in energy metabolism from FAs oxidation to glucose utilization, which is of particular interest as downregulation of lipid metabolism has been shown to reverse or slow the progression of certain central nervous system disorders (Trabjerg et al., 2020). Although meldonium has been recognized for its neuroprotective properties (Sjakste et al., 2005; Pupure et al., 2010a; Isajevs et al., 2011; Beitnere et al., 2014; Demir et al., 2019; Ozaydin et al., 2023), its effects in the context of SAE, one of the most common sepsisassociated complications (Catarina et al., 2021), remain unknown. To clarify the potential effects of meldonium in the SAE, we examined markers of brain injury in rats receiving meldonium via drinking water for 4 weeks prior to induction of abdominal sepsis in two different models.

In SAE, impaired neurobehavior manifests early and is usually evaluated by reflex testing both in intensive care unit settings and in animal models (Pan et al., 2022; Qin et al., 2023). In FIP septic rats, reflexes score began to deteriorate early regardless of the pretreatment, but from the 4th hour onwards, this decline was milder in the M + S group. This finding is consistent with the results of another invasive model, in which meldonium improved the righting reflex in rats after a single i.p. following ethanol-induced neurotoxicity (Zvejniece et al., 2010). However, in both sepsis groups, we observed a slight improvement in reflexes after the 6th and 7th hours following FIP injection. The observed improvement likely reflects contributions from animals that exhibited higher initial scores and a more favourable response to the septic conditions, as those with the lowest initial scores had already succumbed to sepsis. Thus, this apparent improvement reflects the behaviour of rats better able to withstand the sepsis-induced insult and is consistent with previous studies that differentiated individuals based on the severity of sepsis they developed (Horiguchi et al., 2018; Zhang H. et al., 2022).

Sepsis-associated pathophysiological changes leading to impaired neurobehavior, include brain perivascular edema due to the impairment of BBB by both pathogens and systemically elevated pro-inflammatory markers (Kuperberg and Wadgaonkar, 2017). While we did not observe changes in the dry to wet brain mass ratio in sepsis alone, it appears that sepsis preceded by meldonium pretreatment led to water accumulation in the brain, as there was a trend towards a slight decrease in this parameter in both sepsis models, but was statistically significant only in the FIP model. Insufficient perfusion of the brain due to blood vessels being compressed by edema leads to an inadequate supply of oxygen and nutrients, which rapidly manifests as a poor mental state and lowered reflexes score, and can eventually lead to coma or death (Pan et al., 2022; Sekino et al., 2022). We propose that the previously observed high mortality rate in septic rats pretreated with meldonium (Đurašević et al., 2021; 2022) may partly stem from the development of brain edema. Meldonium's carnitine-lowering effects (Dambrova et al., 2016; Berlato and Bairros, 2020; Shaforostova et al., 2021) induce carnitine deficiency, thereby possibly impairing astrocyte function (Trabjerg et al., 2020; Shaforostova et al., 2021; Szrok-Jurga et al., 2023) and potentially predisposing rats to BBB damage and brain edema when they are subjected to sepsis.

Together with BBB impairment, the complex pathophysiology of SAE is marked by an imbalance between generation and scavenging of reactive oxygen species (ROS) and reactive nitrogen species (RNS), triggering reactions that damage macromolecules, thereby compromising cellular structure and function (Sekino et al., 2022). One of the key indicators of cell membrane integrity is the PC/LPC ratio, as PC is essential for membrane stability, while LPC is generated from it during damage and can act as a bioactive lipid, activating pro-inflammatory pathways that further destabilize membranes (Liu et al., 2020). Therefore, a decrease in PC relative to LPC is considered indicative of cell membrane degradation. To better understand the mechanisms underlying the susceptibility of meldoniumpretreated rats to SAE, we measured levels of PAB, AOPP, LPO, and PC/LPC ratios in different brain regions to assess tissue oxidative status and the extent of protein and lipid damage caused by oxidative stress. Given the overwhelming inflammation in response to infection in sepsis, the protein content of the inflammatory markers HMGB1 and haptoglobin was evaluated. We also measured CD73 activity due to its role as a rate-limiting enzyme in converting extracellular ATP (eATP), released by damaged cells, into adenosine, which has been shown to increase in both plasma and brain following i.p. LPS injection (Guo et al., 2024).

Motor control and coordination can be severely impaired in SAE, leading to deficits in balance, posture, and fine motor skills (Zhao et al., 2024). Given the critical role of cerebellum in regulating these processes, we examined the effects of meldonium pretreatment in this brain region of septic rats. In the cerebellum in both sepsis models, oxidative stress was observed, as indicated by increased levels of PAB and LPO. The observed phenomena appear to be localized and primarily target lipids, while sparing proteins from damage, as cerebellar levels of AOPP, and HMGB1, along with CD73 activities, remained unchanged in both models. This was further supported in LPS sepsis by the reduced cerebellar PC/LPC ratio, suggesting that lipids within membranes sustained structural damage, possibly due to increased LPO. A 4-week meldonium pretreatment appears to be sufficient to modulate FA metabolism selectively and inhibit the accumulation of toxic FA derivatives, consistent with the documented neuroprotective effects of meldonium (Sjakste et al., 2005; Pupure et al., 2010a; Isajevs et al., 2011; Beitnere et al., 2014; Demir et al., 2019; Ozaydin et al., 2023). This is also supported by a decreased LPO in the cerebellum of meldonium-pretreated FIP septic rats and an elevated PC/LPC ratio in the same brain region of meldonium-pretreated LPS septic rats.

Medulla oblongata, with its nuclei regulating autonomic functions including heart rate and blood pressure control, may be particularly prone to sepsis-induced damage due to its proximity to the area postrema (Heming et al., 2017). The presented results suggest that sepsis-induced oxidative stress affects protein and lipid compartments in this brain region differently than in the cerebellum. In rats with FIP sepsis, elevated PAB and AOPP levels, along with reduced haptoglobin expression and CD73 activity, indicate significant protein damage in this region. However, oxidative lipid damage appears well controlled, as evidenced by stable LPO levels and PC/LPC ratio. Pretreatment with meldonium might help to prevent the impairment of vital functions regulated by this brain region, as our results showed that all markers of oxidative stress and inflammation in the medulla oblongata of meldonium-pretreated FIP septic rats were maintained at control levels. In the medulla oblongata of LPS septic rats, the observed increase in the PC/LPC ratio, in addition to stable LPO levels, might be associated with certain LPO-independent adjustments in lipid metabolism. Meldonium pretreatment appears to specifically target these LPO-independent processes, as PC/LPC ratio in the medulla oblongata of LPS septic rats was significantly decreased compared to sepsis only.

The prefrontal cortex, crucial for higher cognitive functions, suffers significant impairment due to SAE, leading to severe

cognitive deficits and behavioural changes (Heming et al., 2017). Sepsis-induced damage in this region following FIP sepsis was extensive, as almost all examined markers were disrupted. The observed increase in oxidative stress markers, along with a reduced PC/LPC ratio, haptoglobin levels, and CD73 activity, indicated significant oxidative damage affecting both lipids and proteins. The extent of injury appeared to be lesser in LPS septic rats, in which LPO, AOPP, and haptoglobin levels remained unchanged. In both models, pretreatment with meldonium helped return the PC/LPC ratio to control values, indicating that meldonium selectively affects lipid metabolism in this structure as well. However, the effects of meldonium pretreatment appear to be less pronounced when followed by FIP sepsis, as haptoglobin levels were similar in both septic groups.

Certain model-specific effects of meldonium pretreatment could be attributed to the complex nature of FIP-induced polymicrobial sepsis, whereby it may prevent some aspects of tissue damage, albeit to a limited extent. The FIP model is considered more invasive, as a variety of microbial components and live bacteria are introduced into the peritoneal cavity mimicking clinical cases of peritonitis (Seemann et al., 2017; Tenhunen et al., 2020). In contrast, the LPS model, exposes animals to a single component from the outer cell wall of Gram-negative bacteria, making it a single endotoxin-driven and therefore more controlled form of sepsis (Seemann et al., 2017; Tenhunen et al., 2020). Thus, the FIP model triggers a broader and potentially clinically more relevant inflammation, while the LPS model induces a more straightforward inflammatory response due to being triggered by a single endotoxin (Seemann et al., 2017). Therefore, the LPS model is considered more suitable for studying the molecular mechanisms of sepsis and offers greater reproducibility due to its well-defined induction process, while polymicrobial models (e.g., cecal ligation and puncture (CLP) and FIP) more accurately reflect the physiological changes observed in septic patients (Zhang et al., 2017). The model-specific variations we observed in the context of SAE contribute to the ongoing debate about the suitability of different models for studying various aspects of sepsis (Remick et al., 2000; Zhang et al., 2017). The greater severity of the FIP model was perhaps most evident in the significant reduction in haptoglobin protein content across all three brain regions. This reduction is likely due to the fact that haptoglobin binds and degrades cell-free haemoglobin, and its deficiency further compromises tissue defence against oxidative damage (Spagnuolo et al., 2015). Our findings also emphasize the importance of analysing individual brain regions under septic conditions, rather than the whole brain. Namely, we observed region-specific increases in LPO in both FIP- and LPS-induced sepsis. Our findings in LPS sepsis align with reports of an early and persistent LPO increase in the whole brain of LPS-injected mice (Seemann et al., 2017), but this increase was not observed in polymicrobial sepsis models (Remick et al., 2000; Zhang et al., 2017).

Apart from model-specific differences, the present study also revealed a varying trend of meldonium effects in different brain regions. Interestingly, meldonium prevented a decrease in haptoglobin content in the cerebellum and medulla oblongata, but not in the prefrontal cortex of FIP-septic rats. The lower efficacy of meldonium in the prefrontal cortex, compared to the cerebellum and medulla oblongata of FIP-septic rats, was also evident in the amount of PAB. This might be attributed to the reported differences in the extent of sepsis-induced injury across brain regions (Kafa et al., 2010; Silverman et al., 2014; Heming et al., 2017) which are associated with higher microglial density in the cortical regions and lower density in the cerebellum and brainstem (Tian et al., 2019). Kim et al. observed that neurons in the substantia nigra are more severely damaged under septic conditions than those in the hippocampus and cortex (Kim et al., 2000). Similarly, in septic mice, IL1b expression was higher in the cortex than in the cerebellum and brainstem (Silverman et al., 2014). Therefore, it is plausible to hypothesize that meldonium's efficacy in preventing sepsis-induced injury varies across brain regions due to regional differences in the extent of damage caused by sepsis. It is noteworthy that, in contrast to FIP, PAB levels in the medulla oblongata of LPS septic rats remained elevated despite meldonium pretreatment. This could be attributed to the inherently high basal ROS levels, intense mitochondrial and metabolic activity (Anusha-Kiran et al., 2022), and elevated pro-inflammatory cytokine expression within this region during infection (Soung et al., 2022). These factors, along with LPS model generally considered to cause a more rapid, acute inflammatory response (Đurašević et al., 2022), could limit the efficacy of antioxidant interventions like meldonium.

Purinergic signaling plays an important role in the pathophysiology of sepsis-induced brain injury (Ledderose et al., 2016). A well recognized "danger" signal, eATP, increases in response to cellular damage and inflammation during sepsis and septic shock (Di Virgilio et al., 2009; Ledderose et al., 2016). Through P2X7 as a primary receptor, eATP induces microglial cell activation and migration to injury sites, where they form a barrier between healthy and damaged tissue (Di Virgilio et al., 2009; Monif et al., 2009). However, P2X7 activation is also linked to increased ROS production, exacerbating tissue damage, while P2X7 deletion has been shown to reduce oxidative stress in brains of septic mice (Savio et al., 2017). ATP-dependent signaling mediated by the P2X7 receptor is modulated by ectonucleotidases expressed on the surface of microglial cells, which catalyse a series of hydrolysis steps that break down ATP, with CD73 catalysing the final step, converting AMP to adenosine (Zimmermann, 1992; Savio et al., 2017). The role of CD73 in sepsis-related injury has been recognized mainly through its pharmacological inactivation and studies in knockout animals (Reutershan et al., 2009; Haskó et al., 2011). While its activity within the brain has been previously explored in LPS-induced neuroinflammation (Smith et al., 2014; Miron et al., 2023), it has not yet been studied in polymicrobial sepsis models. Perhaps most remarkably in the present study, is that CD73 activity in the prefrontal cortex is decreased in FIP-septic rats, whereas it is increased in LPS-septic rats. Previous studies reported no changes in brain CD73 activity in response to LPS (Smith et al., 2014; Miron et al., 2023), but this discrepancy might stem from methodological differences, as Miron et al. assessed CD73 activity in the rat cerebral cortex 24 h after the i.p. LPS injection, while Smith et al. measured it in the brain continuously perfused with LPS for 14 or 28 days. Our finding is also in line with a recent study showing that peripheral LPS challenge causes a rapid increase of extracellular adenosine in brain (Guo et al., 2024). Altogether, our findings

suggest that CD73 is involved in the early phases of sepsis as a neuroprotective factor, owing to the massive production of adenosine, which acts as a modulatory, immunosuppressive, antiinflammatory, and protective agent (Haskó et al., 2011; Ledderose et al., 2016; Zhang T. et al., 2022). In line with the protective role of CD73-derived adenosine, several studies have indicated that diminished CD73 function may be a contributing factor to severe or persistent infections (Gao et al., 2022; Xiang et al., 2025). In sepsis, where excessive inflammation and cytokine release occur, increased CD73 activity may reflect the body's attempt to counteract immune overactivation and limit tissue damage. Similar to the previously shown correlation between plasma adenosine levels and septic shock incidence (Gao et al., 2022), we hypothesized that the changes in CD73 activity we observed correlate with the severity or progression of neuroinflammation in SAE.

5 Conclusion

Four weeks of meldonium pretreatment demonstrated neuroprotective effects in septic rats, particularly in the cerebellum and medulla oblongata, with the extent of these effects depending on the sepsis model (FIP vs. LPS). Across both models, however, the benefits of meldonium pretreatment were generally less pronounced in the prefrontal cortex. Our findings highlight the importance of considering both the sepsis model and regional brain variations when modelling SAE and exploring new therapeutic interventions.

5.1 Study limitations and recommendations

While our findings offer important novel insights, several limitations should be considered and addressed in future studies. The short observation window (up to 8 h post-sepsis induction), due to the high mortality rate in the FIP model, limited our ability to assess the long-term effects of meldonium on the progression of SAE. Additionally, although this is the first study to demonstrate the benefits of meldonium pretreatment in the context of SAE, an indepth exploration of the underlying molecular mechanisms of its neuroprotective effects remains necessary. This includes further investigation into the brain edema observed in meldoniumpretreated FIP-septic rats. Regional differences in BBB integrity under septic conditions should also be addressed, as these could help explain the observed discrepancies in the direction of changes in some markers across brain regions. Finally, given the lack of sepsisspecific treatments, our study paves the way for exploring the protective potential of other drugs with similar mode of action similar to meldonium (e.g., perhexiline), which could be successfully repurposed for sepsis treatment.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The animal study was approved by the Veterinary Directorate of the Serbian Ministry of Agriculture, Forestry and Water Management (permits No. 323-07-11574/2021-05 and 323-07-05650/2021-05/1). The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

AR: Data curation, Formal Analysis, Investigation, Methodology, Visualization, Writing - original draft. Writing - review and editing. TS: Investigation, Methodology, Writing - review and editing. KB: Investigation, Methodology, Writing - review and editing. DD: Formal Analysis, Investigation, Methodology, Writing - review and editing. FV: Data curation, Formal Analysis, Investigation, Methodology, Writing - review and editing. AT: Investigation, Methodology, Writing - review and editing. SD: Conceptualization, Funding acquisition, Validation, Writing - review and editing. IL: Conceptualization, Project administration, Supervision, Validation, Writing - original draft, Writing - review and editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia, under the contract numbers 451-03-137/2025-03/200178 and 451-03-136/2025-03/200017.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

10.3389/fphar.2025.1588831

References

Anusha-Kiran, Y., Mol, P., Dey, G., Bhat, F. A., Chatterjee, O., Deolankar, S. C., et al. (2022). Regional heterogeneity in mitochondrial function underlies region specific vulnerability in human brain ageing: implications for neurodegeneration. *Free Radic. Biol. Med.* 193, 34–57. doi:10.1016/j.freeradbiomed.2022.09.027

Aslankoc, R., Savran, M., Ozmen, O., and Asci, S. (2018). Hippocampus and cerebellum damage in sepsis induced by lipopolysaccharide in aged rats - pregabalin can prevent damage. *Biomed. and Pharmacother*. 108, 1384–1392. doi:10.1016/j.biopha. 2018.09.162

Beitnere, U., van Groen, T., Kumar, A., Jansone, B., KlUnited States, V., and Kadish, I. (2014). Mildronate improves cognition and reduces amyloid-β pathology in transgenic Alzheimer's disease mice. *J. Neurosci. Res.* 92, 338–346. doi:10.1002/jnr.23315

Berlato, D. G., and Bairros, A. V. de (2020). Meldonium: pharmacological, toxicological, and analytical aspects. *Toxicol. Res. Appl.* 4, 2397847320915143. doi:10.1177/2397847320915143

Brown, G. C. (2019). The endotoxin hypothesis of neurodegeneration. J. Neuroinflammation 16, 180. doi:10.1186/s12974-019-1564-7

Catarina, A. V., Branchini, G., Bettoni, L., De Oliveira, J. R., and Nunes, F. B. (2021). Sepsis-associated encephalopathy: from pathophysiology to progress in experimental studies. *Mol. Neurobiol.* 58, 2770–2779. doi:10.1007/s12035-021-02303-2

Dambrova, M., Liepinsh, E., and Kalvinsh, I. (2002). Mildronate: cardioprotective action through carnitine-lowering effect. *Trends Cardiovasc. Med.* 12, 275–279. doi:10. 1016/S1050-1738(02)00175-5

Dambrova, M., Makrecka-Kuka, M., Vilskersts, R., Makarova, E., Kuka, J., and Liepinsh, E. (2016). Pharmacological effects of meldonium: biochemical mechanisms and biomarkers of cardiometabolic activity. *Pharmacol. Res.* 113, 771–780. doi:10.1016/j.phrs.2016.01.019

Demir, D., Kuru Bektaşoğlu, P., Koyuncuoğlu, T., Kandemir, C., Akakın, D., Yüksel, M., et al. (2019). Neuroprotective effects of mildronate in a rat model of traumatic brain injury. *Injury* 50, 1586–1592. doi:10.1016/j.injury.2019.08.036

Di Virgilio, F., Ceruti, S., Bramanti, P., and Abbracchio, M. P. (2009). Purinergic signalling in inflammation of the central nervous system. *Trends Neurosci.* 32, 79–87. doi:10.1016/j.tins.2008.11.003

Drakulić, D., Stanojlović, M., Nedeljković, N., Grković, I., Veličković, N., Guševac, I., et al. (2015). Upregulation of nucleoside triphosphate diphosphohydrolase-1 and ecto-5'-nucleotidase in rat hippocampus after repeated low-dose dexamethasone administration. J. Mol. Neurosci. 55, 959–967. doi:10.1007/s12031-014-0452-y

Dumbuya, J. S., Chen, X., Du, J., Li, S., Liang, L., Xie, H., et al. (2023). Hydrogen-rich saline regulates NLRP3 inflammasome activation in sepsis-associated encephalopathy rat model. *Int. Immunopharmacol.* 123, 110758. doi:10.1016/j.intimp.2023.110758

Đurašević, S., Ružičić, A., Lakić, I., Tosti, T., Đurović, S., Glumac, S., et al. (2021). The effects of a meldonium pre-treatment on the course of the faecal-induced sepsis in rats. *Int. J. Mol. Sci.* 22, 9698. doi:10.3390/ijms22189698

Đurašević, S., Ružičić, A., Lakić, I., Tosti, T., Đurović, S., Glumac, S., et al. (2022). The effects of a meldonium pre-treatment on the course of the LPS-induced sepsis in rats. *Int. J. Mol. Sci.* 23, 2395. doi:10.3390/ijms23042395

Đurašević, S., Stojković, M., Bogdanović, L., Pavlović, S., Borković-Mitić, S., Grigorov, I., et al. (2019). The effects of meldonium on the renal acute ischemia/reperfusion injury in rats. *Int. J. Mol. Sci.* 20, 5747. doi:10.3390/ijms20225747

Folch, J., Lees, M., and Sloane Stanley, G. H. (1957). A simple method for the isolation and purification of total lipides from animal tissues. *J. Biol. Chem.* 226, 497–509. doi:10. 1016/s0021-9258(18)64849-5

Gao, J., Chen, S., Kong, T., Wen, D., and Yang, Q. (2022). The relationship between soluble CD73 and the incidence of septic shock in severe sepsis patients: a cross-sectional analysis of data from a prospective FINNAKI study. *Ann. Transl. Med.* 10, 302. doi:10.21037/atm-22-371

Gérard-Monnier, D., Erdelmeier, I., Régnard, K., Moze-Henry, N., Yadan, J.-C., and Chaudière, J. (1998). Reactions of 1-Methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation. *Chem. Res. Toxicol.* 11, 1176–1183. doi:10.1021/tx9701790

Gray, E. G., and Whittaker, V. P. (1962). The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation. *J. Anat.* 96, 79–88.

Guo, Q., Gobbo, D., Zhao, N., Zhang, H., Awuku, N.-O., Liu, Q., et al. (2024). Adenosine triggers early astrocyte reactivity that provokes microglial responses and drives the pathogenesis of sepsis-associated encephalopathy in mice. *Nat. Commun.* 15, 6340. doi:10.1038/s41467-024-50466-y

Haberham, Z. L., van den Brom, W. E., Venker-van Haagen, A. J., Baumans, V., de Groot, H. N., and Hellebrekers, L. J. (1999). EEG evaluation of reflex testing as assessment of depth of pentobarbital anaesthesia in the rat. *Lab. Anim.* 33, 47–57. doi:10.1258/002367799780578570

Haskó, G., Csóka, B., Koscsó, B., Chandra, R., Pacher, P., Thompson, L. F., et al. (2011). Ecto-5'-Nucleotidase (CD73) decreases mortality and organ injury in sepsis. *J. Immunol.* 187, 4256–4267. doi:10.4049/jimmunol.1003379

Heming, N., Mazeraud, A., Verdonk, F., Bozza, F. A., Chrétien, F., and Sharshar, T. (2017). Neuroanatomy of sepsis-associated encephalopathy. *Crit. Care* 21, 65. doi:10. 1186/s13054-017-1643-z

Horiguchi, H., Loftus, T. J., Hawkins, R. B., Raymond, S. L., Stortz, J. A., Hollen, M. K., et al. (2018). Innate immunity in the persistent inflammation, immunosuppression, and catabolism syndrome and its implications for therapy. *Front. Immunol.* 9, 595. doi:10. 3389/fimmu.2018.00595

Isajevs, S., Isajeva, D., Beitnere, U., Jansone, B., Kalvinsh, I., and KlUnited States, V. (2011). Mildronate as a regulator of protein expression in a rat model of Parkinson's disease. *Medicina* 47, 79. doi:10.3390/medicina47100079

Kafa, I. M., Uysal, M., Bakirci, S., and Ayberk Kurt, M. (2010). Sepsis induces apoptotic cell death in different regions of the brain in a rat model of sepsis. *Acta Neurobiol. Exp.* (*Wars*) 70, 246–260. doi:10.55782/ane-2010-1796

Kim, W.-G., Mohney, R. P., Wilson, B., Jeohn, G.-H., Liu, B., and Hong, J.-S. (2000). Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. *J. Neurosci.* 20, 6309–6316. doi:10.1523/JNEUROSCI.20-16-06309.2000

Kirk, R. A., Kesner, R. P., Wang, L.-M., Wu, Q., Towner, R. A., Hoffman, J. M., et al. (2019). Lipopolysaccharide exposure in a rat sepsis model results in hippocampal amyloid-β plaque and phosphorylated tau deposition and corresponding behavioral deficits. *GeroScience* 41, 467–481. doi:10.1007/s11357-019-00089-9

Kotov, S. V., B, K. C., Isakova, E. V., B, H. E., Volchenkova, T. V., B, B. T., et al. (2015). Efficacy of meldonium in acute period of ischemic stroke. *Alm. Clin. Med.*, 75–81. doi:10.18786/2072-0505-2015-39-75-81

Kuperberg, S. J., and Wadgaonkar, R. (2017). Sepsis-associated encephalopathy: the blood-brain barrier and the sphingolipid rheostat. *Front. Immunol.* 8, 597. doi:10.3389/fimmu.2017.00597

Ledderose, C., Bao, Y., Kondo, Y., Fakhari, M., Slubowski, C., Zhang, J., et al. (2016). Purinergic signaling and the immune response in sepsis: a review. *Clin. Ther.* 38, 1054–1065. doi:10.1016/j.clinthera.2016.04.002

Liepinsh, E., Konrade, I., Skapare, E., Pugovics, O., Grinberga, S., Kuka, J., et al. (2011). Mildronate treatment alters γ -butyrobetaine and l-carnitine concentrations in healthy volunteers. *J. Pharm. Pharmacol.* 63, 1195–1201. doi:10.1111/j.2042-7158.2011. 01325.x

Liepinsh, E., Kuka, J., Svalbe, B., Vilskersts, R., Skapare, E., Cirule, H., et al. (2009). Effects of long-term mildronate treatment on cardiac and liver functions in rats. *Basic Clin. Pharmacol. Toxicol.* 105, 387–394. doi:10.1111/j.1742-7843.2009.00461.x

Liu, P., Zhu, W., Chen, C., Yan, B., Zhu, L., Chen, X., et al. (2020). The mechanisms of lysophosphatidylcholine in the development of diseases. *Life Sci.* 247, 117443. doi:10. 1016/j.lfs.2020.117443

Markwell, M. A., Haas, S. M., Bieber, L. L., and Tolbert, N. E. (1978). A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. *Anal. Biochem.* 87, 206–210. doi:10.1016/0003-2697(78)90586-9

Miron, V. V., Assmann, C. E., Mostardeiro, V. B., Bottari, N. B., Baldissarelli, J., Reichert, K. P., et al. (2023). Resistance physical exercise alleviates lipopolysaccharide-triggered neuroinflammation in cortex and hippocampus of rats via purinergic signaling. *NeuroToxicology* 99, 217–225. doi:10.1016/j.neuro.2023.10.011

Monif, M., Reid, C. A., Powell, K. L., Smart, M. L., and Williams, D. A. (2009). The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. J. Neurosci. 29, 3781–3791. doi:10.1523/JNEUROSCI.5512-08.2009

Nair, A. B., and Jacob, S. (2016). A simple practice guide for dose conversion between animals and human. *J. Basic Clin. Pharm.* 7, 27-31. doi:10.4103/0976-0105. 177703

Olivieri, R., Michels, M., Pescador, B., Ávila, P., Abatti, M., Cucker, L., et al. (2018). The additive effect of aging on sepsis-induced cognitive impairment and neuroinflammation. *J. Neuroimmunol.* 314, 1–7. doi:10.1016/j.jneuroim.2017.11.014

Ozaydin, D., Kuru Bektaşoğlu, P., Türe, D., Bozkurt, H., Ergüder, B. İ., Sargon, M. F., et al. (2023). Mildronate has ameliorative effects on the experimental ischemia/ reperfusion injury model in the rabbit spinal cord. *World Neurosurg.* 173, e717-e726. doi:10.1016/j.wneu.2023.02.139

Pan, S., Lv, Z., Wang, R., Shu, H., Yuan, S., Yu, Y., et al. (2022). Sepsis-induced brain dysfunction: pathogenesis, diagnosis, and treatment. *Oxidative Med. Cell. Longev.* 2022, 1328729. doi:10.1155/2022/1328729

Pfister, D., Siegemund, M., Dell-Kuster, S., Smielewski, P., Rüegg, S., Strebel, S. P., et al. (2008). Cerebral perfusion in sepsis-associated delirium. *Crit. Care* 12, R63. doi:10. 1186/cc6891

Pupure, J., Isajevs, S., Skapare, E., Rumaks, J., Svirskis, S., Svirina, D., et al. (2010a). Neuroprotective properties of mildronate, a mitochondria-targeted small molecule. *Neurosci. Lett.* 470, 100–105. doi:10.1016/j.neulet.2009.12.055

Pupure, J., Rumaks, J., Isajevs, S., Korzakova, O., Puncule, J., Svirskis, S., et al. (2010b). Mildronate's protective effects in the peripheral nervous system: stavudine-induced neuropathy and formalin-induced inflammation. *Proc. Latv. Acad. Sci. Sect. B. Nat. Exact, Appl. Sci.* 64, 114–118. doi:10.2478/v10046-010-0032-7 Qin, M., Gao, Y., Guo, S., Lu, X., Zhao, Q., Ge, Z., et al. (2023). Establishment and evaluation of animal models of sepsis-associated encephalopathy. *World J. Emerg. Med.* 14, 349–353. doi:10.5847/wjem.j.1920-8642.2023.088

Remick, D. G., Newcomb, D. E., Bolgos, G. L., and Call, D. R. (2000). Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. *Shock* 13, 110–116. doi:10.1097/00024382-200013020-00004

Reutershan, J., Vollmer, I., Stark, S., Wagner, R., Ngamsri, K.-C., and Eltzschig, H. K. (2009). Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. *FASEB J.* 23, 473–482. doi:10.1096/fj.08-119701

Savio, L. E. B., Andrade, M. G. J., de Andrade Mello, P., Santana, P. T., Moreira-Souza, A. C. A., Kolling, J., et al. (2017). P2X7 receptor signaling contributes to sepsisassociated brain dysfunction. *Mol. Neurobiol.* 54, 6459–6470. doi:10.1007/s12035-016-0168-9

Seemann, S., Zohles, F., and Lupp, A. (2017). Comprehensive comparison of three different animal models for systemic inflammation. *J. Biomed. Sci.* 24, 60. doi:10.1186/s12929-017-0370-8

Sekino, N., Selim, M., and Shehadah, A. (2022). Sepsis-associated brain injury: underlying mechanisms and potential therapeutic strategies for acute and long-term cognitive impairments. *J. Neuroinflammation* 19, 101. doi:10.1186/s12974-022-02464-4

Sesti, C., Simkhovich, B. Z., Kalvinsh, I., and Kloner, R. A. (2006). Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. *J. Cardiovasc. Pharmacol.* 47, 493–499. doi:10.1097/01.fjc.0000211732.76668.d2

Shaforostova, E. A., Gureev, A. P., Vitkalova, I.Yu, and Popov, V. N. (2021). The effect of L-carnitine depletion induced by long-term therapy of mice with meldonium on brain mitochondrial balance. *Biomed. khimiya* 67, 74–80. doi:10.18097/PBMC20216701074

Sharshar, T., Gray, F., Grandmaison, G. L. de la, Hopklnson, N. S., Ross, E., Dorandeu, A., et al. (2003). Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. *Lancet* 362, 1799–1805. doi:10.1016/S0140-6736(03)14899-4

Silverman, H. A., Dancho, M., Regnier-Golanov, A., Nasim, M., Ochani, M., Olofsson, P. S., et al. (2014). Brain region-specific alterations in the gene expression of cytokines, immune cell markers and cholinergic system components during peripheral endotoxin-induced inflammation. *Mol. Med.* 20, 601–611. doi:10.2119/molmed.2014.00147

Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., et al. (2016). The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 315, 801–810. doi:10.1001/jama.2016.0287

Sjakste, N., Gutcaits, A., and Kalvinsh, I. (2005). Mildronate: an antiischemic drug for neurological indications. *CNS Drug Rev.* 11, 151–168. doi:10.1111/j.1527-3458.2005. tb00267.x

Smith, M. D., Bhatt, D. P., Geiger, J. D., and Rosenberger, T. A. (2014). Acetate supplementation modulates brain adenosine metabolizing enzymes and adenosine A₂A receptor levels in rats subjected to neuroinflammation. *J. Neuroinflammation* 11, 99. doi:10.1186/1742-2094-11-99

Soung, A. L., Vanderheiden, A., Nordvig, A. S., Sissoko, C. A., Canoll, P., Mariani, M. B., et al. (2022). COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis. *Brain* 145, 4193–4201. doi:10.1093/brain/awac270

Spagnuolo, M. S., Mollica, M. P., Maresca, B., Cavaliere, G., Cefaliello, C., Trinchese, G., et al. (2015). High fat diet and inflammation – modulation of haptoglobin level in rat brain. *Front. Cell Neurosci.* 9, 479. doi:10.3389/fncel.2015.00479

Stanojlović, M., Horvat, A., Guševac, I., Grković, I., Mitrović, N., Buzadžić, I., et al. (2014). Time course of cerebral hypoperfusion-induced neurodegenerative changes in the cortex of male and female rats. *Folia Biol. (Praha)* 60, 123–132. doi:10.14712/fb2014060030123

Szrok-Jurga, S., Turyn, J., Hebanowska, A., Swierczynski, J., Czumaj, A., Sledzinski, T., et al. (2023). The role of acyl-CoA β -oxidation in brain metabolism and neurodegenerative diseases. Int. J. Mol. Sci. 24, 13977. doi:10.3390/ijms241813977

Tenhunen, A. B., Heijden, J. van der, Blokhin, I., Massaro, F., Hansson, H. A., Feinstein, R., et al. (2020). The antisccretory peptide AF-16 may modulate tissue edema but not inflammation in experimental peritonitis induced sepsis. *PLOS ONE* 15, e0232302. doi:10.1371/journal.pone.0232302

Tian, M., Qingzhen, L., Zhiyang, Y., Chunlong, C., Jiao, D., Zhang, L., et al. (2019). Attractylone attenuates sepsis-associated encephalopathy and cognitive dysfunction by inhibiting microglial activation and neuroinflammation. *J. Cell. Biochem.* 120, 7101–7108. doi:10.1002/jcb.27983

Todorović, A., Bobić, K., Veljković, F., Pejić, S., Glumac, S., Stanković, S., et al. (2024). Comparable toxicity of surface-modified TiO2 nanoparticles: an *in vivo* experimental study on reproductive toxicity in rats. *Antioxidants* 13, 231. doi:10.3390/ antiox13020231

Trabjerg, M. S., Mørkholt, A. S., Lichota, J., Oklinski, M. K. E., Andersen, D. C., Jønsson, K., et al. (2020). Dysregulation of metabolic pathways by carnitine palmitoyl-transferase 1 plays a key role in central nervous system disorders: experimental evidence based on animal models. *Sci. Rep.* 10, 15583. doi:10.1038/s41598-020-72638-8

Xiang, F., Zhang, Z., Nie, Y., Cao, X., Li, Y., Chen, X., et al. (2025). Altered CD73adenosine signaling linked to infection in patients undergoing hemodialysis. *J. Inflamm. Res.* 18, 1267–1279. doi:10.2147/JIR.S498575

Xin, Y., Wang, J., Chu, T., Zhou, Y., Liu, C., and Xu, A. (2022). Electroacupuncture alleviates neuroinflammation by inhibiting the HMGB1 signaling pathway in rats with sepsis-associated encephalopathy. *Brain Sci.* 12, 1732. doi:10.3390/brainsci12121732

Zhang, B., Liu, C., Yang, N., and Wang, X. (2017). A comparative study of changes of autophagy in rat models of CLP versus LPS induced sepsis. *Exp. Ther. Med.* 14, 2194–2200. doi:10.3892/etm.2017.4758

Zhang, H., Feng, Y.-W., and Yao, Y.-M. (2018). Potential therapy strategy: targeting mitochondrial dysfunction in sepsis. *Mil. Med. Res.* 5, 41. doi:10.1186/s40779-018-0187-0

Zhang, H., Xu, J., Wu, Q., Fang, H., Shao, X., Ouyang, X., et al. (2022a). Gut microbiota mediates the susceptibility of mice to sepsis-associated encephalopathy by butyric acid. J. Inflamm. Res. 15, 2103–2119. doi:10.2147/JIR.S350566

Zhang, T., Yu-Jing, L., and Ma, T. (2022b). The immunomodulatory function of adenosine in sepsis. *Front. Immunol.* 13, 936547. doi:10.3389/fimmu.2022.936547

Zhao, Y., Jiang, Y., Shen, Y., and Su, L.-D. (2024). Sepsis impairs purkinje cell functions and motor behaviors through microglia activation. *Cerebellum* 23, 329–339. doi:10.1007/s12311-023-01531-7

Zhu, Y., Zhang, G., Zhao, J., Li, D., Yan, X., Liu, J., et al. (2013). Efficacy and safety of mildronate for acute ischemic stroke: a randomized, double-blind, active-controlled phase II multicenter trial. *Clin. Drug Investig.* 33, 755–760. doi:10.1007/s40261-013-0121-x

Zimmermann, H. (1992). 5'-Nucleotidase: molecular structure and functional aspects. *Biochem. J.* 285 (Pt 2), 345-365. doi:10.1042/bj2850345

Zvejniece, L., Svalbe, B., Makrecka, M., Liepinsh, E., Kalvinsh, I., and Dambrova, M. (2010). Mildronate exerts acute anticonvulsant and antihypnotic effects. *Behav. Pharmacol.* 21, 548–555. doi:10.1097/FBP.0b013e32833d5a59